Literature DB >> 2469889

Age-related effects of angiotensin converting enzyme inhibitors.

A Breckenridge1.   

Abstract

In spite of the fact that plasma renin activity declines with age and drugs whose action is mediated via the renin-angiotensin system might be expected to be less effective with increasing age, the limited available data suggest that both captopril and enalapril lower blood pressure in the elderly. The quantity and the quality of data to compare hypotensive effects in the young and elderly leave much to be desired. It might be predicted that adverse effects such as hypotension and exacerbation of preexisting renal failure could pose problems for the use of these drugs in the elderly, but documentation of this is also sparse. Clearly, this area of risk versus benefit of angiotensin converting enzyme (ACE) inhibitors in the elderly requires further study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2469889

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.

Authors:  S Neldam; B Forsén
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  ACE inhibitors and impotence: a case series from the Spanish drug monitoring system.

Authors:  A Carvajal; M T Lérida; A Sánchez; L H Martín; I M de Diego
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 5.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.